Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Ripple (XRP) Makes Major Wall Street Push With New Institutional Trading Business

Ripple (XRP) Makes Major Wall Street Push With New Institutional Trading Business

CryptopotatoCryptopotato2026/08/27 13:42

The company behind XRP has made another move geared toward Wall Street and beyond its cryptocurrency roots by launching a new institutional trading business with Ripple Prime.

The new initiative, announced earlier on Thursday, will allow hedge funds, asset managers, and other institutional clients to execute Total Return Swaps (TRS) across US-listed equities, indices, and digital assets.

Deeper Into Wall Street

The announcement shared by the company informed that the service is already live, and it aims to expand the firm’s presence in traditional financial markets less than a year after completing its $1.25 billion acquisition of prime broker Hidden Road.

Products within Delta One are derivatives designed to closely track the performance of an underlying asset or index. A TRS, for instance, allows an investor to receive the gains and income generated by an asset without necessarily owning it directly, in exchange for paying financing costs and absorbing losses.

Ripple Prime has expanded the scope of assets available on its platform as clients can now access equities alongside foreign exchange, fixed income, derivatives, and cryptocurrencies through a single counterparty relationship. The company said customers can also cross-margin exposures across those different assets around the clock, potentially reducing the amount of collateral institutions need to maintain separately.

Ripple Prime’s President, Noel Kimmel, said that these sorts of services are what institutional market participants are “asking for today, and we are proud to be the ones delivering it.”

Beyond Crypto

Ripple’s acquisition of Hidden Road (later renamed Ripple Prime) was initially announced in April 2025 and completed by the end of the year. It became the first crypto company to own and operate a global multi-asset prime broker, clearing over $3 trillion annually and serving more than 300 institutional customers.

As reported a few months back, Ripple Prime also received an investment-grade BBB rating from KBRA, with the agency pointing to its growth in clearing and intermediation across exchange-traded derivatives and fixed-income repo markets.

Earlier in August, Ripple Prime announced an upsized $275 million private placement of senior unsecured notes, following a $200 million debt facility secured from Neuberger Specialty Finance in May. The entity said it would use the fresh capital to support its continued expansion.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

On Tuesday, ASML (ASML.US) became the focus of the market as Bank of America praised the company's additional chip manufacturing equipment supply agreements with TSMC (TSM.US), Intel (INTC.US), and Samsung.

智通财经2026/09/09 08:11
"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.

智通财经2026/09/09 08:11
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经2026/09/09 08:11
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions